Long Covid has been part­ly mys­te­ri­ous, due to the nascen­cy of SARS-CoV-2 as well as the vast­ness of lin­ger­ing symp­toms ex­pe­ri­enced by mil­lions of peo­ple world­wide fol­low­ing their ini­tial di­ag­noses.

That makes long Covid quite a wide um­brel­la term and has led to a large gap in R&D, as it ap­pears there’s a gen­er­al un­will­ing­ness of most bio­phar­mas to con­sid­er test­ing their drugs in this con­di­tion. For the most part, drug­mak­ers in­ter­est­ed in Covid-19 have most of their eggs in the pre­ven­tion and acute treat­ment bas­kets through vac­cines, mon­o­clon­al an­ti­bod­ies and an­tivi­rals.

Big Phar­ma and bio­phar­ma alike sure­ly are not done with test­ing new vac­cines and treat­ments for acute Covid-19. And some star­tups are just now emerg­ing to tack­le the pan­dem­ic, as ev­i­denced just this week by the launch of a new mAb biotech — fo­cused on a com­bo ther­a­py for im­muno­com­pro­mised pa­tients — led by Take­da’s for­mer vac­cines chief.

So drug­mak­ers, in­clud­ing the likes of Glax­o­SmithK­line, Vir Biotech­nol­o­gy, Hu­mani­gen, Pfiz­er and Roche, are in­ter­est­ed in the prospects of test­ing their drugs in pa­tients with long Covid, Reuters re­ports.

A Pfiz­er spokesper­son told End­points News in an emailed state­ment that the Big Phar­ma’s clin­i­cal tri­als aren’t cur­rent­ly eval­u­at­ing long Covid, but two stud­ies, EPIC-HR and EPIC-SR, “may pro­vide us with rel­e­vant da­ta to help in­form fu­ture stud­ies.” Those stud­ies of Paxlovid in­clude fol­low-up with pa­tients for six months, the spokesper­son not­ed.

For its part, Hu­mani­gen is test­ing its drug lenzilum­ab in hos­pi­tal­ized Covid-19 pa­tients but does “not have any plans to test long COVID,” the com­pa­ny told End­points in an emailed state­ment.

Re­gen­eron, which makes the emer­gency au­tho­rized pre­ven­ta­tive mAb known as RE­GEN-COV, told End­points that “long COVID is cer­tain­ly an area of in­ter­est for Re­gen­eron, but we have no ac­tive tri­als to in­ves­ti­gate this pop­u­la­tion at this time.”

Roche, mean­while, told End­points that the com­pa­ny rec­og­nizes “pa­tients’ need for Long COVID treat­ment. We are cur­rent­ly look­ing at what we can do to meet this need. It is sim­ply too ear­ly to share con­crete plans.”

Mil­lions of peo­ple glob­al­ly still ex­pe­ri­ence symp­toms months af­ter their ini­tial in­fec­tion, rang­ing from brain fog to gas­troin­testi­nal is­sues to oth­er res­pi­ra­to­ry dif­fi­cul­ties. But Big Phar­ma has seemed to fall to the way­side in cre­at­ing and test­ing treat­ments for this large pa­tient pop­u­la­tion.

So it’s main­ly been ju­nior drug de­vel­op­ers and biotechs with­out any ap­proved meds that have tried test­ing or plan to study their drugs in long Covid.

That list in­cludes Ax­cel­la Ther­a­peu­tics (with an in­ves­ti­ga­tion­al NASH med); NLS Phar­ma­ceu­tics; First Wave Bio­Phar­ma (for GI in­fec­tions as­so­ci­at­ed with long Covid); Am­pio Phar­ma­ceu­ti­cals; Re­gen­cell Bio­sciences; Or­gan­i­cell; Aim Im­munotech; Tonix Phar­ma­ceu­ti­cals (mid-stage study slat­ed first half of this year); Virios Ther­a­peu­tics; Pieris Phar­ma­ceu­ti­cals; NI­AID-col­lab­o­rat­ed Hu­ma­net­ics; and oth­ers, ac­cord­ing to an End­points re­view of SEC fil­ings, com­pa­ny state­ments and pipelines.

A bevy of com­pa­nies ditched their Covid-19 as­sets be­fore mak­ing it to mar­ket, whether for tri­al fail­ures, pipeline pri­or­i­ti­za­tion or claim­ing that there were enough treat­ments al­ready avail­able.

The same could hap­pen for bio­phar­mas work­ing on long Covid, and it’s al­ready hap­pened for Atea Phar­ma­ceu­ti­cals. Roche’s $350 mil­lion up­front cash bet on Atea blew up in Oc­to­ber 2021 when the biotech’s an­tivi­ral AT-527 flunked a mid-stage test. Roche called it quits on the pact a month lat­er.

Atea al­so ditched a six-month fol­low-on study of its an­tivi­ral AT-527 that was look­ing at the drug’s im­pact on long Covid in up to 1,000 pa­tients.

The cur­rent plan, an Atea spokesper­son told End­points, is to de­vel­op be­m­ni­fos­bu­vir (AT-527) as a “pre­ferred back­bone of com­bi­na­tion ther­a­py for COVID-19. At this time, our pro­gram does not in­clude plans for long-COVID.”

The EMA is putting EU member states on alert over the shortage of two drugs that counter heart attacks due to an uptick in demand.

On Friday, the EMA sent out a warning that two Boehringer Ingelheim drugs are experiencing a shortage: Actilyse and Metalyse. The drugs are used as emergency treatments for adults experiencing acute myocardial infarction, or a heart attack, by dissolving blood clots that have formed in the blood vessels.

Fujifilm’s CDMO arm, Fujifilm Diosynth, has been on a roll this month as the company has recently broken ground on a major project in Europe and it appears to be keeping up the momentum.

Fujifilm Diosynth announced that it has kicked off an expansion project for its microbial manufacturing facility at its campus in the town of Billingham, UK, in the northeast of England.

The 20,000 square-foot, £400 million ($435 million) expansion will add clean rooms, purification suites and a packing area along with more space for the manufacturing itself.

Back in April, Amgen said it was encouraged by the solicitor general’s anticipated review of its Supreme Court petition to rehear a Repatha patent case. They’re likely much less optimistic about the outcome now.

Solicitor General Elizabeth Prelogar wrote in a recent 27-page brief that Amgen’s arguments “lack merit and further review is not warranted.”

The case traces back to a suit filed in 2014 against Sanofi and Regeneron’s Praluent, which ended up beating Amgen’s PCSK9 blockbuster Repatha to market by a month just a year later.